BR112022024999A2 - Inibidor tlr7 em combinação com prednisolona ou hidroxicloroquina para o tratamento do lúpus eritematoso cutâneo - Google Patents
Inibidor tlr7 em combinação com prednisolona ou hidroxicloroquina para o tratamento do lúpus eritematoso cutâneoInfo
- Publication number
- BR112022024999A2 BR112022024999A2 BR112022024999A BR112022024999A BR112022024999A2 BR 112022024999 A2 BR112022024999 A2 BR 112022024999A2 BR 112022024999 A BR112022024999 A BR 112022024999A BR 112022024999 A BR112022024999 A BR 112022024999A BR 112022024999 A2 BR112022024999 A2 BR 112022024999A2
- Authority
- BR
- Brazil
- Prior art keywords
- prednisolone
- combination
- lupus erythematosus
- hydroxychloroquin
- cutaneous lupus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202011024586 | 2020-06-11 | ||
| PCT/US2021/036740 WO2021252718A1 (en) | 2020-06-11 | 2021-06-10 | Tlr7 inhibitor in combination with prednisolone or hydroxychloroquine for treating cutaneous lupus erythematosus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022024999A2 true BR112022024999A2 (pt) | 2022-12-27 |
Family
ID=76959055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022024999A BR112022024999A2 (pt) | 2020-06-11 | 2021-06-10 | Inibidor tlr7 em combinação com prednisolona ou hidroxicloroquina para o tratamento do lúpus eritematoso cutâneo |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230310408A1 (https=) |
| EP (1) | EP4164639A1 (https=) |
| JP (2) | JP7751597B2 (https=) |
| KR (1) | KR20230023717A (https=) |
| CN (1) | CN115701995A (https=) |
| AU (1) | AU2021286582A1 (https=) |
| BR (1) | BR112022024999A2 (https=) |
| CA (1) | CA3181964A1 (https=) |
| IL (1) | IL298667A (https=) |
| MX (1) | MX2022015760A (https=) |
| WO (1) | WO2021252718A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230171469A (ko) | 2021-04-16 | 2023-12-20 | 길리애드 사이언시즈, 인코포레이티드 | 티에노피롤 화합물 |
| EP4398989A1 (en) | 2021-09-10 | 2024-07-17 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| AU2024356361A1 (en) * | 2023-10-02 | 2026-04-02 | Bristol-Myers Squibb Company | A method of treating lupus |
| TW202535949A (zh) | 2023-12-20 | 2025-09-16 | 美商必治妥美雅史谷比公司 | 靶向IL-18受體β(IL-18RB)之抗體及相關方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060270707A1 (en) | 2005-05-24 | 2006-11-30 | Zeldis Jerome B | Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus |
| EP2582398B1 (en) * | 2010-06-16 | 2016-04-13 | Dynavax Technologies Corporation | Methods of treatment using tlr7 and/or tlr9 inhibitors |
| AU2013203815A1 (en) * | 2010-06-16 | 2013-05-02 | Dynavax Technologies Corporation | Methods of treatment using TLR7 and/or TLR9 inhibitors |
| WO2015200094A1 (en) * | 2014-06-20 | 2015-12-30 | Baylor Research Institute | Methods and compositions for systemic lupus erythematosus (sle) therapy |
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
-
2021
- 2021-06-10 KR KR1020237000739A patent/KR20230023717A/ko active Pending
- 2021-06-10 CN CN202180040836.2A patent/CN115701995A/zh active Pending
- 2021-06-10 WO PCT/US2021/036740 patent/WO2021252718A1/en not_active Ceased
- 2021-06-10 MX MX2022015760A patent/MX2022015760A/es unknown
- 2021-06-10 EP EP21742945.5A patent/EP4164639A1/en active Pending
- 2021-06-10 JP JP2022575941A patent/JP7751597B2/ja active Active
- 2021-06-10 US US18/009,035 patent/US20230310408A1/en active Pending
- 2021-06-10 AU AU2021286582A patent/AU2021286582A1/en active Pending
- 2021-06-10 CA CA3181964A patent/CA3181964A1/en active Pending
- 2021-06-10 BR BR112022024999A patent/BR112022024999A2/pt unknown
- 2021-06-10 IL IL298667A patent/IL298667A/en unknown
-
2025
- 2025-09-26 JP JP2025159926A patent/JP2025183420A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230310408A1 (en) | 2023-10-05 |
| JP7751597B2 (ja) | 2025-10-08 |
| KR20230023717A (ko) | 2023-02-17 |
| WO2021252718A1 (en) | 2021-12-16 |
| EP4164639A1 (en) | 2023-04-19 |
| AU2021286582A1 (en) | 2023-02-09 |
| MX2022015760A (es) | 2023-01-19 |
| JP2025183420A (ja) | 2025-12-16 |
| CN115701995A (zh) | 2023-02-14 |
| JP2023530264A (ja) | 2023-07-14 |
| CA3181964A1 (en) | 2021-12-16 |
| IL298667A (en) | 2023-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022024999A2 (pt) | Inibidor tlr7 em combinação com prednisolona ou hidroxicloroquina para o tratamento do lúpus eritematoso cutâneo | |
| BR112022009571A2 (pt) | Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras | |
| BR112022017891A2 (pt) | Métodos para tratar a infecção por coronavírus e lesão pulmonar induzida por inflamação resultante | |
| CR20210563A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| BR112021018739A2 (pt) | Composições e métodos para o tratamento de doenças ou distúrbios associados a kras | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| BR112023002573A2 (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de infecção viral e distúrbio respiratório e método de inibição de protease viral | |
| BR112023002453A2 (pt) | Composições de agente de via de estresse de replicação e métodos para tratar câncer | |
| BR112022016360A2 (pt) | Uso de inibidores de sglt-2 para a prevenção e/ou tratamento de doenças cardíacas em felinos | |
| MX2025003477A (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| BR112021017314A2 (pt) | Uso de extrato de elaeocarpus sylvestris | |
| BR112023025738A2 (pt) | Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção | |
| MX2025001990A (es) | Agente terapeutico y metodo terapeutico que son para pacientes con cancer que presentan deterioro funcional de la proteina del retinoblastoma (rb1) y que implican el uso concomitante de inhibidor del factor de transcripcion 1 de mielina (myt1) y agente quimioterapeutico | |
| BR112022018948A2 (pt) | Métodos de tratamento de lesão pulmonar com inibidores de cgrp | |
| BR112022018115A2 (pt) | Inibidor de cxcr4 para o tratamento de síndrome de desconforto respiratório agudo e infecções virais | |
| BR112022018396A2 (pt) | Método de tratamento ou prevenção para insuficiência cardíaca crônica | |
| MX2024007862A (es) | Una composicion farmaceutica inyectable para el tratamiento de enfermedades respiratorias en animales. | |
| BR112022025920A2 (pt) | Tratamento de artrite reumatoide | |
| BR112021018815A2 (pt) | Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário | |
| IL296890A (en) | Caspase inhibitors to enhance injury repair and to treat bacterial and viral infections | |
| MX2022011596A (es) | Compuestos para tratar o prevenir una infeccion por coronaviridae y metodos y usos para evaluar la aparicion de una infeccion por coronaviridae. | |
| MX2025004758A (es) | Compuestos y su uso para el tratamiento de hemoglobinopatias | |
| MX2008002456A (es) | Uso de ambroxol para el tratamiento de infecciones por rinovirus. | |
| MX2021001228A (es) | Composicion para uso en la prevencion y/o tratamiento de la mucosa genitourinaria. | |
| BR112022025900A2 (pt) | Formulações tópicas de (1s)-1-fenil-2-piridin-2-iletanamina |